肿瘤坏死因子相关凋亡诱导配体的凋亡诱导机制及其药物开发

肿瘤坏死因子相关凋亡诱导配体(TRAIL)是TNF超家族成员,它与死亡受体(death receptor,DR)结合,启动细胞内信号途径,特异性诱导肿瘤细胞等凋亡,一般不对机体正常组织产生毒性效应,可望成为新型抗肿瘤药物.然而TRAIL可能的肝细胞毒性严重阻碍其临床应用.本文就TRAIL诱导凋亡的机制及其TRAIL药物开发的前景作一综述.

Mechanism of TNF Related Apoptosis Inducing Ligand Inducing Apoptosis and Its Pharmaceutical Exploitation

TNF related apoptosis inducing ligand(TRAIL) belongs to TNF(tumor necrosis factor) superfamily. It's binding to death receptor (DR) initiate cellular signaling,and specially induces the apoptosis in tumor cells but not in normal tissue cells. So TRAIL seems to be a promising agent,but the possible hepatocyte toxicity of TRAIL severely impedes its clinical use. This paper reviews the mechanism of TRAIL inducing apoptosis and the prospect of TRAIL pharmaceutical exploitation.